MentionFox
Home › funding signals › Natsar Pharmaceuticals, Inc.
Form D · on the record

Natsar Pharmaceuticals — $4.22M Form D filing, May 2026

Natsar Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2026-05-08.

Get the full cited report on Natsar Pharmaceuticals, Inc.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

See a sample report

Just raised? Share it.

Natsar Pharmaceuticals, Inc.: Raised $4.22M, Form D filed 2026-05-08

What do you want to do with Natsar Pharmaceuticals, Inc.?

Key facts

  • · Form D filed with the SEC · Form D
  • · Sold to date: $4.22M · Form D
  • · Total offering: Indefinite · Form D
  • · First sale: 2026-04-23 · Form D
  • · Investors already in: 15 · Form D

Natsar Pharmaceuticals, Inc.

New Form D on file · 2026-05-08 · the record

$4.22M
raise on the record
D
filing
15
investors in
MARYLAND
based
Open the record →

What the record says

FilingForm D
Filed2026-05-08
Industry groupPharmaceuticals
Entity typeCorporation
Incorporated inDELAWARE
BasedELLICOTT CITY, MARYLAND
CIK2134002
Accession0002134002-26-000001
Pharmaceuticals · by week
This raise, $4.22M, filed week of May 4

Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $4.22M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Natsar Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Natsar Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Natsar Pharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on Target: the verdict, 16 sections, 39 cited sources, dated 2026-09-28A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Natsar Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Natsar Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

More on Natsar Pharmaceuticals, Inc.

Cite this page

Permanent URL: https://mentionfox.com/funding/natsar-pharmaceuticals-inc-form-d-26000001
Last updated 2026-09-26
Primary record: SEC filing 1 · SEC filing 2
Natsar Pharmaceuticals raised $4.22M — SEC Form D filing, May 2026. MentionFox, 2026-09-26. https://mentionfox.com/funding/natsar-pharmaceuticals-inc-form-d-26000001